Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Income from Continuing Operations (2020 - 2025)

Oncology Institute (TOI) has disclosed Income from Continuing Operations for 6 consecutive years, with 16504000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 2.43% year-over-year to 16504000.0, compared with a TTM value of 66280000.0 through Sep 2025, up 5.63%, and an annual FY2024 reading of 64663000.0, up 22.16% over the prior year.
  • Income from Continuing Operations was 16504000.0 for Q3 2025 at Oncology Institute, up from 17009000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19286000.0 in Q1 2022 and bottomed at 29998000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 11045001.79, with a median of 15479000.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 2869.26% in 2021, while the deepest fall reached 2108.96% in 2021.
  • Year by year, Income from Continuing Operations stood at 10156000.0 in 2021, then decreased by 8.38% to 11007000.0 in 2022, then plummeted by 70.38% to 18754000.0 in 2023, then grew by 29.71% to 13182000.0 in 2024, then decreased by 25.2% to 16504000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TOI at 16504000.0 in Q3 2025, 17009000.0 in Q2 2025, and 19585000.0 in Q1 2025.